1. In this randomized controlled trial, over a period of 240 weeks, solanezumab did not slow cognitive decline as compared to placebo in patients with preclinical Alzheimer’s disease. 2. Solanezumab did not change the levels of amyloid levels in the brain as compared to placebo in persons with preclinical Alzheimer’s disease. Evidence Rating Level: 1 (Excellent)
Alzheimer's Disease Trial Designs Struggle To Turn Noise Into Sound :: Pink Sheet informa.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from informa.com Daily Mail and Mail on Sunday newspapers.
Cognitive Tests Taken at Home Are on Par with In-Clinic Assessments alzforum.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from alzforum.org Daily Mail and Mail on Sunday newspapers.
A person's ability to self-reflect is associated with cognition and glucose metabolism later in life, a new study finds. Those who engage in more self-reflection had improved cognition, better overall brain health, and increased glucose metabolism later in life.